港股異動 | 再鼎醫藥(9688.HK)續漲超6%創新高 獲高盛首予“買入”評級
格隆匯9月29日丨昨日首日上市收漲8.54%的再鼎醫藥(9688.HK)今日高開高走,盤中高見651港元再創上市新高,現報648港元,漲6.23%,暫成交1億港元,最新總市值556億港元。公司為一間創新型、立足研發及處於商業階段的生物製藥公司,已於2017年9月在美國納斯達克上市,本次在香港二次上市擬全球發售1056.405萬股,其中香港發售89.8萬股,每手50股,發行價562港元。高盛最新發研報指,公司具有已證明的資產選擇能力、較強的執行力以及商業化能力,公司管理團隊經驗豐富,相信公司有潛力成長為中國領先的國內生物技術公司。該行首次覆蓋再鼎醫藥並予買入評級,目標價705.01港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.